1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Autor: D. Tougeron, L. Dahan, F. El Hajbi, K. Le Malicot, L. Evesque, T. Aparicio, O. Bouche, N. Bonichon Lamichhane, B. Chibaudel, A. Angelergues, null A. bodere, J.M. Phelip, M. Mabro, P. Artru, C. Louvet

Publikováno v: Annals of Oncology. 33:S1099-S1100

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::14fcdeebe5e19223d404272d950f11fe
https://doi.org/10.1016/j.annonc.2022.07.1322

LBA28 Prognostic effect of imaging and CEA follow-up in resected colorectal cancer (CRC): Final results and relapse free survival (RFS) - PRODIGE 13 a FFCD phase III trial

Autor: C. Lepage, J.M. Phelip, L. Cany, E. Barbier, S. Manfredi, P. Deguiral, R. Faroux, M. Baconnier, D. Pezet, E. Terrebonne, A. Adenis, M. Ben Abdelghani, J.F. Ain, G. Breysacher, I. Boillot Benedetto, A. Pelaquier, A. Lievre, P. Laurent Puig, F. Bibeau, O. Bouche

Publikováno v: Annals of Oncology. 33:S1395

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4bd8d01b9740854f1c79ffe90bacd1a3
https://doi.org/10.1016/j.annonc.2022.08.024

387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial

Autor: Sophie Gourgou, E. Francois, Françoise Farace, Valérie Boige, S. Garinet, Nicolas Lachaux, V. Lebrun-Ly, L. Mineur, J.M. Phelip, Hélène Blons, M. Ben Abdelghani, V. Polivka, O. Bouche

Publikováno v: Annals of Oncology. 32:S532-S533

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a278edd6d20af6652ae619f3bfef1e8d
https://doi.org/10.1016/j.annonc.2021.08.909

Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease

Autor: Bernard Flourié, Gilles Boschetti, Xavier Roblin, Stéphane Nancey, Laurent Peyrin-Biroulet, Emilie Deltedesco, Stéphane Paul, Nicolas Williet, J.M. Phelip, Gérard Duru

Publikováno v: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases, 2017, 23 (11), pp.2048-2053. ⟨10.1097/MIB.0000000000001223⟩
Inflammatory Bowel Diseases, Lippincott, Williams & Wilkins, 2017, 23 (11), pp.2048-2053. ⟨10.1097/MIB.0000000000001223⟩

International audience; BACKGROUND: Several studies have reported a strong correlation between infliximab (IFX) trough levels (trough levels of infliximab [TLI]) and clinical remission (CR). We aimed to determine threshold values of TLI associated wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::569d924e7d56b090981c264d671f7cf7
https://doi.org/10.1097/mib.0000000000001223

52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial

Autor: Emilie Soularue, F. Ghiringhelli, Vincent Bourgeois, Romain Coriat, Julien Edeline, Emilie Barbier, Pierre Michel, Samy Louafi, Laetitia Dahan, Sylvain Manfredi, Eric Terrebonne, V. Ly Lebrun, J.M. Phelip, Yann Molin, Jérôme Desramé, Thierry Lecomte, David Malka, Hervé Perrier, F. Khemissa Akouz, Cindy Neuzillet

Publikováno v: Annals of Oncology. 31:S260-S261

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae7357d90fc33a67dc6678f5093f8f91
https://doi.org/10.1016/j.annonc.2020.08.030